Okyo Pharma Ltd. (OKYO) intrinsic value & 10-year financials
Okyo Pharma Ltd. (OKYO) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 106.7%
- Free cash flow (FY2025)
- -$1.8M
OKYO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$4.7M | -$0.20 | -$1.8M | — | 106.7% |
| FY2024 | — | -$16.8M | -$0.57 | — | — | — |
| FY2023 | — | -$13.3M | -$0.61 | -$7.7M | — | — |
| FY2022 | — | -$5.4M | -$0.36 | -$5.5M | — | — |
| FY2021 | — | -$3.4M | -$0.32 | -$1.6M | — | — |
| FY2020 | — | -$1.5M | — | — | — | — |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
OKYO Pharma Ltd revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
OKYO Pharma Ltd has earned high returns on invested capital, averaging 106.7% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
OKYO Pharma Ltd capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
OKYO Pharma Ltd is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.